SynAct Pharma AB announced that the composition of the Nomination Committee prior to the Annual General Meeting on 25 May 2023 has changed as a result of a change of ownership.
Following the change, the Nomination Committee for the 2023 Annual General Meeting consists of the following persons: Niels Ankerstjerne Sloth, appointed by Bioinvest ApS; Per Colleen, appointed by TomEnterprise Public Capital AB; Jens Bager, appointed by GL Capital AB; and Torbjørn Bjerke, Chairman of the Board. Jens Bager remains as Chairman of the Nomination Committee.